Secondary and tertiary sulfonamides: a patent review (2008-2012)

被引:72
作者
Scozzafava, Andrea [1 ]
Carta, Fabrizio [1 ]
Supuran, Claudiu T. [2 ]
机构
[1] Univ Florence, Lab Chim Bioinorgan, I-50019 Florence, Italy
[2] Univ Firenze, Dipartimento Sci Farmaceut, I-50019 Florence, Italy
关键词
anti-virals; cancer; cardiac disorders; CNS diseases; herbicides; inflammation; substituted sulfonamide; INHIBITORS;
D O I
10.1517/13543776.2013.742065
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Introduction: Secondary and tertiary sulfonamides (R-SO2NR1R2) are defined by the single or double N-alkyl or N-aryl/heteroaryl substitution of the primary sulfonamide respectively. They can be obtained easily by the classical S(N)2 or nucleophile acyl substitution displacements using the appropriate synthones. Many classes of compounds used in therapy present the substituted sulfonamide groups and there is also a continuous interest in different fields such as the herbicides herein schematically reported. Areas covered: The intent of this article is to give a comprehensive overview of the most important patents in the last decade related to pathologies of great interest. All selected patents claim new compounds bearing the secondary or/and tertiary sulfonamide moiety, and state to have biological activities. The article is neither intended for detailed discussions of the sulfonamides mode of action on the specific therapeutic targets, nor for their contribution to the physicochemical properties of the molecules they are introduced into, as the scientific literature in such topics is exhaustive and in many cases, debates are still ongoing. The main fields covered are related to pathologies affecting the CNS, cardiac disorders, anti-virals, inflammation diseases, glaucoma, bone remodeling, anti-cancer, and finally a section is also dedicated to herbicides. Expert opinion: The insertion of the secondary/tertiary sulfonamide group into the organic scaffolds is chemically straightforward and not associated to particular toxicity in the cells or in the organisms. Therefore, it is possible to create large libraries of compounds, which can be tested for different diseases. As demonstrated by the patents reported in the present review, the research in medicinal chemistry, and other fields, takes big advantages as new leads are created, and might be further developed.
引用
收藏
页码:203 / 213
页数:11
相关论文
共 85 条
[1]  
Anglada L, 2005, N-[3-3-Substituted-pyrazoIo[1,5-a] pyrimidin-7-yI]sulfonamides, and compositions and methods related thereto, Patent No. [WO014597, 014597]
[2]  
[Anonymous], 2009, WO Pat., Patent No. 012242
[3]  
Armstrong HM, 2005, Substituted sulfonamides, Patent No. [WO027837, 027837]
[4]  
Bai DL, 2003, Patent No. [6605635 B1, 6605635]
[5]  
Baker RK, 2008, Substituted diazepine sulfonamides as bombesin receptor subtype-3 modulators, Patent No. [WO073311, 073311]
[6]  
Barker E, 2005, Imidazopyridine derivatives which interact with the G-protein coupled receptor family, Patent No. [WO056532, 056532]
[7]  
Beaudoin S, 2009, Sodium channels inhibitors, Patent No. [WO012241, 012241]
[8]   Systemic neuropeptide levels as predictive indicators for lethal outcome in patients with postoperative sepsis [J].
Beer, S ;
Weighardt, H ;
Emmanuilidis, K ;
Harzenetter, MD ;
Matevossian, E ;
Heidecke, CD ;
Bartels, H ;
Siewert, JR ;
Holzmann, B .
CRITICAL CARE MEDICINE, 2002, 30 (08) :1794-1798
[9]  
Bender W, 2002, Naphthyl substituted, and anilide substituted sulfonamides, Patent No. [US6417181, 6417181]
[10]   Alleviation of mechanical and thermal allodynia by CGRP8-37 in a rodent model of chronic central pain [J].
Bennett, AD ;
Chastain, KM ;
Hulsebosch, CE .
PAIN, 2000, 86 (1-2) :163-175